US FDA waives second pivotal trial for MAP's migraine treatment Levadex
This article was originally published in Scrip
The US FDA does not require a second pivotal study of MAP Pharmaceuticals' inhaled acute migraine treatment Levadex (MAP004), after the first study hit all four of its primary endpoints, the company said.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.